NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free NSPR Stock Alerts $2.28 +0.03 (+1.33%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$2.25▼$2.3850-Day Range$2.26▼$3.1552-Week Range$0.96▼$3.85Volume25,082 shsAverage Volume25,116 shsMarket Capitalization$53.53 millionP/E RatioN/ADividend YieldN/APrice Target$4.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get InspireMD alerts: Email Address InspireMD MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.6% Upside$4.85 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.61) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.69 out of 5 starsMedical Sector675th out of 939 stocksSurgical & Medical Instruments Industry70th out of 98 stocks 3.5 Analyst's Opinion Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.85, InspireMD has a forecasted upside of 112.6% from its current price of $2.28.Amount of Analyst CoverageInspireMD has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NSPR. Previous Next 0.0 Dividend Strength Dividend YieldInspireMD does not currently pay a dividend.Dividend GrowthInspireMD does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NSPR. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for InspireMD this week, compared to 0 articles on an average week.Search Interest2 people have searched for NSPR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added InspireMD to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InspireMD insiders have not sold or bought any company stock.Percentage Held by Insiders21.62% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for InspireMD are expected to grow in the coming year, from ($0.61) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InspireMD is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InspireMD is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInspireMD has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About InspireMD Stock (NYSE:NSPR)InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Read More NSPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NSPR Stock News HeadlinesMarch 26, 2024 | globenewswire.comInspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024March 23, 2024 | americanbankingnews.comInspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.comMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 6, 2024 | finanznachrichten.deInspireMD, Inc.: InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | investorplace.comNSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comInspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | benzinga.comPreview: InspireMD's EarningsFebruary 28, 2024 | globenewswire.comInspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6thMarch 28, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 21, 2024 | ca.finance.yahoo.comNSPR Mar 2024 7.500 callFebruary 1, 2024 | msn.comInspireMD Announces CE Mark Recertification Under MDRFebruary 1, 2024 | msn.comInspireMD Secures CE Mark Recertification Under New EU StandardsJanuary 23, 2024 | finance.yahoo.comWe're Hopeful That InspireMD (NASDAQ:NSPR) Will Use Its Cash WiselyNovember 27, 2023 | msn.comInspireMD (NSPR) Price Target Increased by 11.49% to 4.95November 23, 2023 | msn.comDown -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a TurnaroundNovember 6, 2023 | markets.businessinsider.comInspireMD earnings: here's what Wall Street expectsNovember 6, 2023 | msn.comInspireMD GAAP EPS of -$0.15 misses by $0.01, revenue of $1.56M beats by $0.06MNovember 6, 2023 | finance.yahoo.comInspireMD Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 3, 2023 | msn.comInspireMD Q3 2023 Earnings PreviewNovember 1, 2023 | markets.businessinsider.comInspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23September 25, 2023 | markets.businessinsider.comPiper Sandler Remains a Buy on InspireMD (NSPR)September 22, 2023 | finance.yahoo.comInspireMD's CGuard(TM) Carotid Embolic Prevention System Featured in Live Case at Cracow Vascular Summit 2017 in PolandAugust 31, 2023 | msn.comInspireMD (NSPR) Price Target Increased by 5.45% to 4.44August 16, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn SituationAugust 3, 2023 | msn.comInspireMD (NSPR) Price Target Increased by 6.45% to 4.21July 6, 2023 | msn.comInspireMD (NSPR) Price Target Decreased by 18.42% to 3.95June 26, 2023 | finanznachrichten.deInspireMD, Inc.: InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical TrialSee More Headlines Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today3/27/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:NSPR CUSIPN/A CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$4.85 High Stock Price Target$5.20 Low Stock Price Target$4.50 Potential Upside/Downside+112.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,920,000.00 Net Margins-320.97% Pretax Margin-319.92% Return on Equity-55.71% Return on Assets-46.53% Debt Debt-to-Equity RatioN/A Current Ratio7.34 Quick Ratio6.99 Sales & Book Value Annual Sales$6.20 million Price / Sales8.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book1.25Miscellaneous Outstanding Shares23,460,000Free Float18,386,000Market Cap$53.53 million OptionableOptionable Beta0.84 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Marvin L. Slosman (Age 60)President, CEO & Director Comp: $696.81kMr. Craig Shore (Age 63)CFO, Chief Administrative Officer, Secretary & Treasurer Comp: $625.24kMr. Andrea Tommasoli (Age 52)Chief Operating Officer Comp: $359.27kMr. Amir KohenVice President of Finance & Human ResourcesMr. Shane Thomas Gleason (Age 49)Chief Commercial Officer Dr. Patrick A. Verta DVM (Age 66)M.D., MS Stat, Executive Vice President of Clinical & Medical Affairs Mr. Pete LigottiExecutive VP & GM of North AmericaDr. Sol J. Barer Ph.D. (Age 77)Special Advisor to the Board Comp: $13.92kMore ExecutivesKey CompetitorsIceCure MedicalNASDAQ:ICCMCarmellNASDAQ:CTCXCytosorbentsNASDAQ:CTSOPro-DexNASDAQ:PDEXBeyond AirNASDAQ:XAIRView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 298,406 shares on 2/15/2024Ownership: 9.589%Northern Trust CorpBought 28,438 shares on 2/13/2024Ownership: 0.132%McKinley Carter Wealth Services Inc.Bought 10,000 shares on 2/7/2024Ownership: 0.046%Gary S RoubinBought 50,000 shares on 11/30/2023Total: $126,500.00 ($2.53/share)Paul StukaBought 175,000 shares on 5/12/2023Total: $285,250.00 ($1.63/share)View All Insider TransactionsView All Institutional Transactions NSPR Stock Analysis - Frequently Asked Questions Should I buy or sell InspireMD stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NSPR shares. View NSPR analyst ratings or view top-rated stocks. What is InspireMD's stock price target for 2024? 1 Wall Street analysts have issued 1 year target prices for InspireMD's stock. Their NSPR share price targets range from $4.50 to $5.20. On average, they expect the company's share price to reach $4.85 in the next year. This suggests a possible upside of 112.6% from the stock's current price. View analysts price targets for NSPR or view top-rated stocks among Wall Street analysts. How have NSPR shares performed in 2024? InspireMD's stock was trading at $2.81 on January 1st, 2024. Since then, NSPR stock has decreased by 18.8% and is now trading at $2.2816. View the best growth stocks for 2024 here. When is InspireMD's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NSPR earnings forecast. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) announced its earnings results on Wednesday, March, 6th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The business earned $1.76 million during the quarter, compared to analyst estimates of $1.65 million. InspireMD had a negative net margin of 320.97% and a negative trailing twelve-month return on equity of 55.71%. During the same quarter last year, the firm earned ($0.60) earnings per share. What other stocks do shareholders of InspireMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other InspireMD investors own include Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA), Acasti Pharma (ACST), AcelRx Pharmaceuticals (ACRX), Acorda Therapeutics (ACOR), Aurora Cannabis (ACB) and Ambev (ABEV). Who are InspireMD's major shareholders? InspireMD's stock is owned by a number of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (9.59%), Northern Trust Corp (0.13%), McKinley Carter Wealth Services Inc. (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gary S Roubin and Paul Stuka. View institutional ownership trends. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NSPR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.